Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
Ernexa Therapeutics has completed process development for its lead candidate ERNA-101 and transitioned to GMP manufacturing. Technology transfer activities are now underway, supporting a planned Investigational New Drug (IND) submission in the third quarter of 2026.
Key figures
- Drug Name
- ERNA-101
- Ind submission target
- Q3 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.